# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price ...
Evercore ISI Group analyst Cory Kasimov initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and an...
This capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it...
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional impr...
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $3...
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expect...